Navigation Links
Double impact vaccine

The virus strain which produces the measles vaccine is effective for another purpose - fighting lymphoma, a group of cancers that originate in the lymphatic system.

The Scientists from Mayo clinic department of molecular medicine have found that the measles vaccine virus caused remission of lymphoma in mice injected with human cells containing the cancer.//

Adele Fielding, lead Researcher describes the findings as an early step in potentially developing the measles vaccine virus into a treatment for patients with advanced lymphomas. The study involves the use of the derivatives of the Edmonston-B, strain of the measels vaccine to study its effects on the lymphomas.

Dr. Feilding cited that injecting the vaccine strain of the virus into the tumor caused remission of the human B- cell lymphoma in labaoratory mice with the cancer. Intravenous administration of the same resulted in considerable slowing of tumor progression in mice.

A pilot study is now underway at Mayo clinic to test the use of live measles vaccine virus in patients diagnosed with lymphoma.

The two main types of Lymphoma include Hodgkin's disease and non Hodgkin's lymphoma, each having its own spread, growth and response to treatment. Chemotherapy alone or in combination with radiation therapy is the standard treatment for lymphoma. High dose chemotherapy with bone marrow transplantation is given in case of relapse.

If proved effective, the treatment derived from measles vaccine virus would become another treatment option for patients with relapsed lymphoma.
'"/>




Page: 1

Related medicine news :

1. Consumption Of Red Meat Found To Double The Risk of Rheumatoid Arthritis
2. Early Retirement Age Found To Double Death Rate
3. China Doubles Its Investment In AIDS/HIV Treatment.
4. Ireland’s First Double Lung Transplan
5. Twins in Double Trouble , Desperately Need Heart Transplant
6. Double Kidney Transplants to Solve Organ Donor Shortage
7. Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy
8. Drug Addicts In US Expected To Double By 2020
9. High Doses Of Common Pain killers Can Double The Chances Of Heart attack
10. A 24 Year Old Girls Undergoes Double Mastectomy To Prevent Breast Cancer
11. High Carb Diet Doubles Fat Loss
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2017)... Texas (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity ... available in prints in a wide range of sizes. These illustrations are also ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, ... webinar, they will present the line of epMotion automated liquid handling system. This ... can automate everyday pipetting tasks. , Ideal for scientists and lab technicians with ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... assistance and financial planning services to communities in east Texas, is launching a ... Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: